#UCB #Brussels #Belgium #antibody engineering #Cradle

UCB and Cradle Join Forces to Transform Antibody Engineering

New Avenues for Drug Discovery

In a significant move for biopharmaceutical innovation, UCB, a leading global biopharmaceutical company, has announced a strategic collaboration with Cradle, a pioneering company known for its AI-driven protein design and engineering platform. This partnership marks another milestone in UCB's commitment to enhance its digital antibody discovery and engineering program, which combines cutting-edge technology, deep biological insights, and a robust network of research partners.

UCB, headquartered in Brussels, Belgium, has long been at the forefront of developing treatments for patients suffering from severe diseases, particularly those affecting the immune and central nervous systems. Cradle, based in Amsterdam, specializes in developing advanced tools that facilitate the protein engineering process across different phases of drug discovery. Together, these companies aim to leverage their unique strengths to streamline the development of innovative therapies.

Streamlining the Drug Development Pipeline

As part of this collaboration, UCB plans to utilize Cradle's sophisticated platform in selected research projects, specifically during the phases of hit generation, lead optimization, and preclinical readiness. According to Alistair Henry, Chief Scientific Officer of UCB, this partnership is about harnessing AI to significantly enhance human expertise across various scientific domains, including biology, chemistry, and translational research. The dual effort will ensure that UCB can uncover and refine high-quality candidates for medical conditions that currently lack effective treatment options.

Henry emphasized the significance of using AI not merely for its own sake, but as a strategic tool that amplifies human capabilities. This will facilitate a more rigorous and translational application of computational methods throughout the discovery process, enabling researchers to design better therapeutic molecules more efficiently.

Continuous Learning through AI Integration

An exciting aspect of the UCB-Cradle partnership involves a unique feedback mechanism referred to as a 'lab-in-the-loop' model. In this system, experimental results gleaned from the Cradle platform can be utilized to continuously update program-specific predictive models. This creates a compounding learning process that empowers scientists to utilize their expertise to fine-tune candidates based on the multitude of properties required for therapeutic success. This innovative approach not only enhances candidate selection but also expedites the progression towards viable medications.

Stef van Grieken, CEO and Co-Founder of Cradle, highlighted the importance of scaling the use of AI beyond individual projects to fundamentally alter how scientists approach the drug development process. By integrating Cradle’s capabilities across UCB's extensive biotherapeutics pipeline, this collaboration is set to enable a more cohesive application of AI across various programs, modalities, and complex engineering challenges.

A Vision for the Future

The implications of this partnership extend far beyond just an improvement in drug development metrics. It reflects a broader vision of utilizing AI to foster clinical advancements in biotechnology and pharmaceuticals. The design of effective therapies will likely see significant acceleration as researchers explore novel applications of AI, aided by Cradle’s comprehensive platform. The collaboration promises to usher in a new era of therapeutic innovation, ultimately allowing UCB to deliver better treatment options for patients swiftly and efficiently.

UCB's dedication to transformation through science, coupled with Cradle's technological ingenuity, presents a rich opportunity for breakthroughs in the treatment of complex diseases. As both companies continue to integrate their operations, the future of antibody engineering looks promising, toward tangible outcomes that could redefine current standards in patient care.

For more information on this trailblazing partnership, visit UCB's and Cradle's respective websites to stay updated on their latest developments and advancements in biopharmaceutical innovations.